icon-folder.gif   Conference Reports for NATAP  
 
  9th International
Workshop on HIV and Aging
13 and 14 September 2018
New York City, NY
Back grey_arrow_rt.gif
 
 
Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Treatment-experienced, Virologically Suppressed (EMERALD) and Treatment-naÔve (AMBER) Patients: Week 48 Subgroup Analysis by Age
 
 
  Reported by Jules Levin
9TH INTERNATIONAL WORKSHOP ON HIV AND AGING;
SEPTEMBER 13-14, 2018; NEW YORK CITY, NEW YORK
 
Karam Mounzer,1,* Peter Shalit,2 Cristina Mussini,3 Christoph D. Spinner,4 Romana Petrovic,5 John Jezorwski,6 Keith Dunn,7 Eric Y. Wong7
1Philadelphia FIGHT, Philadelphia, PA, USA; 2Tribal Med, Seattle, WA, USA; 3University of Modena and Reggio Emilia, Modena, Italy; 4Technische Universitšt Munchen, Munich, Germany;
5Janssen Research & Development, Beerse, Belgium; 6Janssen Research & Development, LLC, Pennington, NJ, USA; 7Janssen Scientific Affairs, LLC, Titusville, NJ, USA.

0924181

0924182

0924183

0924184

0924185

0924186

0924187

0924188

0924189

09241810

09241811